SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:lup.lub.lu.se:bbbbd5be-3c02-4fd1-98d0-333d68370b51"
 

Search: id:"swepub:oai:lup.lub.lu.se:bbbbd5be-3c02-4fd1-98d0-333d68370b51" > The fibrinogen clea...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Carter, Richard I. (author)

The fibrinogen cleavage product A alpha-Val(360), a specific marker of neutrophil elastase activity in vivo

  • Article/chapterEnglish2011

Publisher, publication year, extent ...

  • 2011-05-26
  • BMJ,2011

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:bbbbd5be-3c02-4fd1-98d0-333d68370b51
  • https://lup.lub.lu.se/record/2072547URI
  • https://doi.org/10.1136/thx.2010.154690DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Background Alpha-1-antitrypsin (A1AT) deficiency is the only recognised genetic risk factor for chronic obstructive pulmonary disease (COPD), a leading cause of morbidity and mortality worldwide. Since A1AT is the major inhibitor of neutrophil elastase (NE), this enzyme has become widely implicated in the pathogenesis of COPD in general; however, there is currently no specific biomarker for its pre-inhibition activity. Such a biomarker should be a measure of elastase-specific COPD disease activity with the potential to assess early targeted therapeutic intervention, in contrast to traditional and non-specific disease severity markers such as forced expiratory volume in 1 s. Methods In pilot studies, plasma A alpha-Val(360) and markers of neutrophil activation were measured in 95 subjects with a range of A1AT concentrations. A alpha-Val(360) and sputum elastase activity were also measured in a further seven PiZ A1AT-deficient subjects over the course of an acute exacerbation. Finally, A alpha-Val(360) was measured in plasma from subjects randomised to receive A1AT replacement or placebo in the EXACTLE trial. Results The plasma concentrations of A alpha-Val(360) and A1AT related exponentially, consistent with previous theoretical and in vitro experimental data. L-233 (an intracellular NE inhibitor) blocked generation of A alpha-Val(360) and subsequent A1AT/NE complex formation. A alpha-Val(360) was related to the spirometric severity of lung disease in A1AT deficiency, to sputum elastase activity in acute exacerbations and was decreased in subjects receiving A1AT replacement therapy (while remaining constant in those receiving placebo). Conclusions A alpha-Val(360) represents the first specific footprint of pre-inhibition NE activity and is a potential biomarker of disease activity and progression in subjects with elastase-dependent COPD.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Mumford, Richard A. (author)
  • Treonze, Kelly M. (author)
  • Finke, Paul E. (author)
  • Davies, Phillip (author)
  • Si, Qian (author)
  • Humes, John L. (author)
  • Dirksen, Asger (author)
  • Piitulainen, EevaLund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)lung-epi (author)
  • Ahmad, Ali (author)
  • Stockley, Robert A. (author)
  • Lungmedicin, allergologi och palliativ medicinSektion II (creator_code:org_t)

Related titles

  • In:Thorax: BMJ66:8, s. 686-6911468-32960040-6376

Internet link

Find in a library

  • Thorax (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view